PT - JOURNAL ARTICLE AU - Jessica R. McCann AU - Nathan A. Bihlmeyer AU - Kimberly Roche AU - Cameron Catherine AU - Jayanth Jawahar AU - Lydia Coulter Kwee AU - Noelle E. Younge AU - Justin Silverman AU - Olga Ilkayeva AU - Charles Sarria AU - Alexandra Zizzi AU - Janet Wootton AU - Lisa Poppe AU - Paul Anderson AU - Michelle Arlotto AU - Zhengzheng Wei AU - Joshua A. Granek AU - Raphael H. Valdivia AU - Lawrence A. David AU - Holly K. Dressman AU - Christopher B. Newgard AU - Svati H. Shah AU - Patrick C. Seed AU - John F. Rawls AU - Sarah C. Armstrong TI - The Pediatric Obesity Microbiome and Metabolism Study (POMMS): Methods, Baseline Data, and Early Insights AID - 10.1101/2020.06.09.20126763 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20126763 4099 - http://medrxiv.org/content/early/2020/06/14/2020.06.09.20126763.short 4100 - http://medrxiv.org/content/early/2020/06/14/2020.06.09.20126763.full AB - Objective To establish a biorepository of clinical, metabolomic, and microbiome samples from adolescents with obesity as they undergo lifestyle modification.Methods We enrolled 223 adolescents aged 10-18 years with Body Mass Index ≥ 95th percentile, along with 71 healthy weight participants. We collected clinical data, fasting serum, and fecal samples at repeated intervals over 6 months. Here we present our study design, data collection methods, and an interim analysis, including targeted serum metabolite measurements and fecal 16S rRNA gene amplicon sequencing among adolescents with obesity (n=27) and healthy weight controls (n=27).Results Adolescents with obesity have higher serum alanine aminotransferase, C-reactive protein, and glycated hemoglobin, and lower high-density lipoprotein cholesterol when compared with healthy weight controls. Metabolomics revealed differences in branched chain amino acid related metabolites. We also observed differential abundance of specific microbial taxa and lower species diversity among adolescents with obesity when compared with the healthy weight group.Conclusions The Duke Pediatric Metabolism and Microbiome Study biorepository is available as a shared resource. Early findings suggest evidence of a metabolic signature of obesity unique to adolescents, along with confirmation of previously reported findings describing metabolic and microbiome markers of obesity.Clinical Trial Registration Biorepository: NCT02959034Observational Trial: NCT03139877What is already known about this subject?The intestinal microbiome plays an important role in adult obesity and regulation of metabolism. Although it is well-established that obesity has its roots in childhood, very little is known about the role of the microbiome in pediatric obesity and how it changes during adolescence.What are the new findings in your manuscript?This manuscript provides details of a new shared biorepository including clinical data, stool samples and plasma samples from a diverse cohort of 223 adolescents with obesity followed longitudinally over 6 months during a weight management intervention, as well as 71 adolescents with healthy weight as a comparison group.Interim analyses suggest that adolescents with obesity have microbiome signatures and metabolite profiles similar to adults, however key differences in microbial communities and metabolic by-products are identified.How might your results change the direction of research or focus of clinical practice?The POMMS biorepository will be available for investigators to use in future research, to elucidate the underlying mechanisms of obesity and related chronic health conditions.Preliminary data reveal metabolite profiles that suggest adolescence may be a window of metabolic plasticity and disease reversibilityMicrobiome and metabolomic signatures suggest potential biomarkers that may serve as prognostic or predictive factors in disease remission, or targets for future therapeutics.Competing Interest StatementSvati H. Shah, Christopher B. Newgard: Unlicensed patent on a related finding. Raphael H. Valdivia is a founder at Bloom Sciences, (San Diego, CA). All other authors have declared no conflicts of interest. Clinical TrialNCT03139877Clinical Protocols https://sites.duke.edu/pomms Funding StatementNational Institutes of Health R24-DK110492 American Heart Association 17SFRN33670990 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design and procedures were approved by the Duke Institutional Review Board. Eligible participants had parental consent and child assent for the observational study and long-term storage and future use of clinical data and biospecimens.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is either included as a supplemental file or has been uploaded to SRA/github. Some links are still in progress.